Understanding, predicting, and treating depression in pregnancy to improve mothers and offspring mental health outcomes

Acronym

HappyMums

Description of the granted funding

HappyMums is designed to improve our understanding on the biological mechanisms underlying the development of depressive symptoms in pregnancy, and the efficacy of interventions. It will interrogate a large collection of cohorts with multiple biological, medical, clinical, socio-demographic and environmental and lifestyle data to identify the most robust risk factors triggering depressive symptoms, but also moderators of the risk. By putting together unique human samples of placenta, chorionic villi and amniotic fluid, and animal models, HappyMums will improve the understanding of the neurobiological mechanisms affected by depressive symptoms in pregnancy that lead to alterations in the foetal environment, shaping offspring risk for developing negative mental outcomes. The use of three complimentary rodent models will allow to achieve a proof of causality, and the presence of an innovative fish model will elucidate the mechanisms specific to placenta by which adverse maternal conditions are transmitted to the offspring without the potentially confounding mitigating effects of compensatory postnatal maternal care. This knowledge will allow the identification of new targets for the development of novel medications, for the repurposing of existing medications or for the development of non-pharmacological interventions. HappyMums will also develop a digital platform where AI tools-based data can be collected, together with biological, clinical, medical, environmental and lifestyle data, through a mobile phone App that will be at the interface with clinicians via a dedicated dashboard. This will allow early screening of depressive symptoms, prompt diagnoses, personalized treatments, and the promotion of protective lifestyle attitudes. Overall, HappyMums will not only increase the knowledge in the field of mental disorders in pregnancy, but also improve the wellbeing of these women, providing unprecedented benefits also to the offspring and thus to society at large.
Show more

Starting year

2022

End year

2026

Granted funding

676 152 €
Participant
TOMMY'S (UK)
Participant
SOCIETA MARCE ITALIANA PER LA SALUTE MENTALE PERINATALE (IT)
89 462 €
Participant
AARHUS UNIVERSITET (DK)
467 812 €
Participant
UNIVERSITA DEGLI STUDI DI MILANO (IT)
1 620 416 €
Coordinator
HRVATSKO KATOLICKO SVEUCILISTE (HR)
323 250 €
Participant
OSPEDALE SAN RAFFAELE SRL (IT)
650 575 €
Participant
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US)
449 375 €
Participant
AB.ACUS SRL (IT)
560 975 €
Participant
SWPS UNIWERSYTET HUMANISTYCZNOSPOLECZNY (PL)
246 312 €
Participant
UNIVERSITAT ZURICH (CH)
Participant
KING'S COLLEGE LONDON (UK)
Participant
WAGENINGEN UNIVERSITY (NL)
480 246 €
Participant
UNIVERSITEIT VAN AMSTERDAM (NL)
328 851 €
Participant
UNIVERSITAT DE BARCELONA (ES)
938 306 €
Participant
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL)
1 392 533 €
Participant
CHARITE - UNIVERSITAETSMEDIZIN BERLIN (DE)
700 976 €
Participant

Amount granted

8 925 241 €

Funder

European Union

Funding instrument

HORIZON Research and Innovation Actions

Framework programme

Horizon Europe (HORIZON)

Call

Programme part
Health (11673)
Health throughout the Life Course (11689)
Topic
Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients (HORIZON-HLTH-2021-STAYHLTH-01-02)
Call ID
HORIZON-HLTH-2021-STAYHLTH-01

Other information

Funding decision number

101057390

Identified topics

gynecology, pediatrics